<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of hepatitis A virus infection in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of hepatitis A virus infection in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of hepatitis A virus infection in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rubén E Quirós-Tejeira, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth B Rand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although the reported cases of hepatitis A virus (HAV) infection have decreased with the advent of routine childhood immunization, HAV infection is still a frequently reported disease in the United States  (<a class="graphic graphic_figure graphicRef134981" href="/d/graphic/134981.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef134984" href="/d/graphic/134984.html" rel="external">figure 2</a>) [<a href="#rid1">1</a>].</p><p>The clinical manifestations, prevention, diagnosis, and management of HAV infection in children will be discussed below. HAV infection in adults and in newborn infants is discussed in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/2692.html" rel="external">"Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/4958.html" rel="external">"Hepatitis viruses and the newborn: Clinical manifestations and treatment"</a>.)</p><p class="headingAnchor" id="H3607667907"><span class="h1">VIROLOGY</span><span class="headingEndMark"> — </span>HAV is a 27-nm, single-stranded, icosahedral, nonenveloped RNA virus that belongs to the <em>Heparnavirus</em> genus of the Picornaviridae. Four well-defined genotypes of HAV have been described in humans, yet they belong to a single serotype [<a href="#rid2">2</a>]. The virus is stable at low pH and moderate temperature, but it is inactivated by high temperature, chlorine, and formalin. These characteristics are relevant for preventive measures.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – HAV infection occurs worldwide  (<a class="graphic graphic_figure graphicRef69392" href="/d/graphic/69392.html" rel="external">figure 3</a>). In the United States, HAV remains one of the most commonly reported vaccine-preventable diseases [<a href="#rid1">1,3</a>], but the incidence has declined substantially since vaccination was recommended for persons at increased risk (in 1996), for children living in states with the highest incidence of HAV (in 1999), and for all children (in 2006) [<a href="#rid4">4</a>]. The incidence of acute HAV infection in the United States declined from 12 cases per 100,000 in 1995 to approximately 0.4 cases per 100,000 in 2011 [<a href="#rid5">5,6</a>]. Declines were greatest in states in which routine vaccination of children for HAV was initiated in 1999.</p><p></p><p class="bulletIndent1">However, after 2016, there was a marked increase in HAV cases in the United States, rising to 5.7 cases per 100,000 by 2019. The increase is believed to be related to unprecedented person-to-person outbreaks reported in 31 states, primarily involving people experiencing homelessness and with little effect on the pediatric population  (<a class="graphic graphic_figure graphicRef134981" href="/d/graphic/134981.html" rel="external">figure 1</a>) [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/d/html/2692.html" rel="external">"Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1">A decline in the incidence of HAV infection was seen in Israel following a universal immunization program for toddlers initiated in 1999 [<a href="#rid9">9-11</a>]. The incidence declined from 50.4 cases per 100,000 in 1993-1998 to 2.2 to 2.5 cases per 100,000 in 2002-2004, and outbreaks in school and daycare settings were essentially eliminated.</p><p></p><p class="bulletIndent1">The extent to which the observed reductions in the incidence of HAV infection in these reports can be attributed to improved environmental and hygienic conditions or variation in the epidemic cycle is difficult to evaluate [<a href="#rid12">12</a>]. Nonetheless, the above reports highlight the potential for "herd protection" through the immunization of toddlers or children [<a href="#rid4">4,9,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission</strong> – HAV is spread via the fecal-oral route. The majority of patients who acquire the illness have had personal contact with an infected person. In the childcare setting, spread of HAV usually takes place before the index case has been recognized. Outbreaks are usually recognized only after childcare staff members develop symptoms, such as jaundice, since most of the children are asymptomatic or have nonspecific symptoms [<a href="#rid3">3,13</a>]. The potential for broad exposure is compounded in childcare centers that include children who have not yet been toilet-trained [<a href="#rid14">14</a>]. (See <a class="local">'Clinical manifestations'</a> below.)</p><p></p><p class="bulletIndent1">Community, restaurant, and school outbreaks due to contaminated water or food have been described. In the United States, clusters of cases have been seen around international adoptions, many of which occurred in non-travelling contacts of adoptees [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/16709.html" rel="external">"International adoption: Infectious disease aspects", section on 'Hepatitis A virus'</a> and  <a class="medical medical_review" href="/d/html/89453.html" rel="external">"International adoption: Immunization considerations", section on 'Hepatitis A vaccine'</a>.)</p><p></p><p class="bulletIndent1">Nosocomial spread of HAV is rare [<a href="#rid16">16-18</a>]. Among these reports include outbreaks in neonatal intensive care units where newborns were infected through blood-product transfusions and later transmitted the virus to other neonates and the units' staff members [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">The incubation period for HAV is 15 to 50 days. HAV RNA can be detected in stools at least one week before the onset of histologic and biochemical evidence of hepatitis [<a href="#rid19">19</a>], and it can be detected for at least 33 days after the onset of disease  (<a class="graphic graphic_figure graphicRef57931" href="/d/graphic/57931.html" rel="external">figure 4</a>) [<a href="#rid20">20</a>]. In neonates and younger children, HAV RNA can be detected in stools for several months [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The degree of hepatic injury during HAV infection depends upon the host's immune response. HAV infection traditionally has been considered a biphasic process [<a href="#rid21">21</a>]. In the first phase, a noncytopathic stage, viral replication occurs exclusively within the cytoplasm of the hepatocyte. During this first phase, HAV is released into the bile in the absence of elevation of the liver enzymes. Therefore, fecal shedding of HAV starts before the elevation of alanine aminotransferase (ALT)  (<a class="graphic graphic_figure graphicRef57931" href="/d/graphic/57931.html" rel="external">figure 4</a>). This phase is followed by a second phase, a cytopathic stage, with florid portal zone infiltration, necrosis, and erosion of the limiting plate and elevated ALT  (<a class="graphic graphic_figure graphicRef57931" href="/d/graphic/57931.html" rel="external">figure 4</a>). Hepatocellular damage and destruction is not the result of a direct cytopathic effect by HAV but a process mediated by human leukocyte antigen (HLA)-restricted, HAV-specific CD8 lymphocytes and natural killer cells [<a href="#rid22">22-24</a>]. (See  <a class="medical medical_review" href="/d/html/2692.html" rel="external">"Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Interferon gamma appears to have a central role in promoting clearance of infected hepatocytes [<a href="#rid22">22</a>]. An excessive host response, reflected by a marked reduction in HAV RNA during acute infection, is associated with severe hepatitis and a possible fulminant course [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>HAV infection in children is typically an acute, self-limited illness associated with general, nonspecific symptoms, such as fever, malaise, anorexia, vomiting, nausea, abdominal pain or discomfort, and diarrhea. </p><p>Symptoms typically develop between 15 and 50 days after exposure (average 28 days) [<a href="#rid26">26</a>]. During the prodromal period, aminotransferases are typically elevated. Jaundice (conjugated hyperbilirubinemia) usually occurs one week after onset of symptoms, along with choluria (bilirubin in the urine) and mild hepatomegaly [<a href="#rid27">27</a>].</p><p>Symptomatic hepatitis occurs in approximately 30 percent of infected children younger than six years, some of whom become jaundiced. When it does occur, jaundice usually lasts for less than two weeks. Conjugated bilirubin and aminotransferases return to normal within two to three months [<a href="#rid28">28</a>].</p><p>In contrast, older children and adults with HAV infection are usually symptomatic for several weeks. Approximately 70 percent are jaundiced, 80 percent have hepatomegaly, and 40 percent are hospitalized [<a href="#rid5">5,21,27</a>]. Symptoms lasting for up to six months have been described [<a href="#rid29">29</a>].</p><p>Acute liver failure is rare, occurring in less than 1 percent of cases. The case fatality for HAV infection varies with age. In 2001, the case fatality rate was 0.3 percent in children younger than 14 years and 0.1 percent in adolescents and young adults (15 to 39 years) [<a href="#rid30">30</a>]. Acute liver failure secondary to HAV infection is more common in those with underlying liver disease such as hepatitis C [<a href="#rid31">31</a>]. HAV is responsible for less than 1 percent of acute liver failure in children in the United States [<a href="#rid32">32</a>] and up to 80 percent of liver failure in Latin America or other countries in which HAV infection is endemic. (See  <a class="medical medical_review" href="/d/html/16142.html" rel="external">"Acute liver failure in children: Etiology and evaluation"</a>.)</p><p>The most common extrahepatic manifestations of HAV infection include an evanescent maculopapular rash (11 percent) and arthralgias (14 percent) [<a href="#rid33">33</a>]. Much less common extrahepatic manifestations include vasculitis, arthritis, optic neuritis, transverse myelitis, encephalitis, and bone marrow suppression [<a href="#rid34">34</a>].</p><p>HAV rarely is associated with a relapsing pattern. It may also trigger autoimmune hepatitis in genetically predisposed hosts [<a href="#rid35">35-37</a>]. (See  <a class="medical medical_review" href="/d/html/2692.html" rel="external">"Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis", section on 'Extrahepatic manifestations'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>HAV infection should be suspected in a patient presenting with nonspecific symptoms (fever, malaise, anorexia, vomiting, nausea, abdominal pain or discomfort, and diarrhea), sometimes followed by development of jaundice and mild hepatomegaly approximately one week later, with marked elevations in serum aminotransferases and bilirubin. Many individuals, especially young children, have few or no symptoms. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>The diagnosis of acute HAV infection is confirmed by the detection of anti-HAV immunoglobulin M (IgM), which is the gold standard for the detection of acute illness. This antibody is positive at the onset of symptoms, peaks during the acute or early convalescent phase of the disease, and remains positive for approximately four to six months  (<a class="graphic graphic_figure graphicRef57931" href="/d/graphic/57931.html" rel="external">figure 4</a>). Anti-HAV IgM may persist at a low titer for 12 to 14 months in patients with a relapsing or protracted course [<a href="#rid38">38</a>].</p><p>The serologic detection of antibodies is simpler, easier, and less expensive than other techniques, such as HAV detection in stool and body fluids by electron microscopy and HAV RNA detection in stool, body fluids, serum, and liver tissue. Immunoglobulin G (IgG) anti-HAV appears early in the convalescent phase of the disease and remains detectable for decades.</p><p>There may be special considerations when assessing anti-HAV antibodies. In adults, antibodies become detectable two weeks after HAV vaccination, but titers are 10- to 100-fold lower than levels induced by wild-type infection [<a href="#rid39">39,40</a>]. Similar data are not available in children. (See  <a class="medical medical_review" href="/d/html/2692.html" rel="external">"Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">PREVENTION AND PROPHYLAXIS</span></p><p class="headingAnchor" id="H7"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Since HAV is transmitted predominantly by the fecal-oral route, prevention can be aided by improved sanitary conditions, adherence to sanitary practices (eg, handwashing), heating foods appropriately, and avoidance of water and foods from endemic areas. Handwashing is highly effective in preventing the transmission of the virus since HAV may survive for up to four hours on the fingertips. Chlorination and certain disinfecting solutions (household bleach 1:100 dilution) are sufficient to inactivate the virus. (See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Hygienic practices'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Routine childhood vaccination</span><span class="headingEndMark"> — </span>In January 2006, <a class="drug drug_pediatric" data-topicid="12935" href="/d/drug information/12935.html" rel="external">hepatitis A vaccine</a> was added to the recommended childhood and adolescent immunization schedule in the United States [<a href="#rid3">3</a>]. Hepatitis A vaccine is administered in a two-dose schedule and is recommended for all children at one year of age (ie, 12 to 23 months) and as a catch-up vaccine for all children and adolescents 2 to 18 years who have not previously received the vaccine [<a href="#rid41">41</a>].</p><p>A compelling argument for universal vaccination of children is the observation that the disease tends to be more severe when acquired at older ages. In a report from the Centers of Disease Control and Prevention, for example, hospitalization was required in 13 percent of children younger than five years, compared with 31 percent of older children and adults [<a href="#rid30">30</a>]. Because humans are the only known reservoir for HAV, universal immunization strategies could hypothetically eradicate HAV.</p><p>Guidance from the World Health Organization permits the option of a single-dose (off-label) vaccine schedule for children one year and older; this strategy may be useful during hepatitis A outbreaks. (See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Limited role for single-dose strategy'</a>.)</p><p class="headingAnchor" id="H1865709269"><span class="h2">Vaccination of high-risk groups</span><span class="headingEndMark"> — </span>In addition to the routine childhood vaccination described above, vaccination is recommended for all nonimmune members of high-risk groups, including [<a href="#rid41">41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Arriving international adoptees from endemic areas (≥1 year of age) and their close contacts</p><p class="bulletIndent1"><span class="glyph">●</span>International travelers to endemic areas (including infants ≥6 months of age)</p><p class="bulletIndent1"><span class="glyph">●</span>People with HIV (≥1 year of age)</p><p class="bulletIndent1"><span class="glyph">●</span>People with chronic liver disease (≥1 year of age)</p><p></p><p>If the vaccine is given to infants 6 to &lt;12 months (ie, because of travel), this does not count towards the routine two-dose vaccination series [<a href="#rid41">41</a>]. Vaccination of adults in these and other high-risk groups is discussed separately. (See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Pre-exposure prophylaxis</span><span class="headingEndMark"> — </span>The primary tool for protection against hepatitis A prior to exposure is vaccination, which is superior to <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> with respect to achievable antibody concentrations and durability of immune response. Administration of immune globulin is warranted for selected nonimmune individuals at risk for hepatitis A exposure. Indications for each of these interventions are outlined in the table  (<a class="graphic graphic_table graphicRef119479" href="/d/graphic/119479.html" rel="external">table 1</a>) and discussed separately. (See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Passive immunization'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Post-exposure prophylaxis</span><span class="headingEndMark"> — </span>Post-exposure prophylaxis to individuals exposed to HAV consists of <a class="drug drug_pediatric" data-topicid="12935" href="/d/drug information/12935.html" rel="external">hepatitis A vaccine</a> and/or <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a>, depending on the patient characteristics. Indications for and detailed recommendations about post-exposure prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Protection following exposure'</a>.)</p><p class="headingAnchor" id="H2042706239"><span class="h2">Return to school or daycare</span><span class="headingEndMark"> — </span>Children should not return to school or daycare until one week after onset of the illness, until the prophylaxis program for contacts is completed, or until directed by the responsible health department [<a href="#rid26">26</a>]. In addition, adherence to universal precautions is crucial since HAV may be present in stool for several months after the initial onset of disease [<a href="#rid18">18,20</a>]. Post-exposure prophylaxis and universal precautions are discussed separately. (See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span></p><p>Treatment of acute HAV infection is supportive. HAV infection in children is usually a minor and self-limited infection; as mentioned above, HAV is often asymptomatic or associated only with symptoms indistinguishable from nonspecific viral gastrointestinal infections. The usual supportive measures for fever and diarrhea may be undertaken. (See  <a class="medical medical_review" href="/d/html/5992.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Management and prevention"</a> and  <a class="medical medical_review" href="/d/html/5989.html" rel="external">"Fever in infants and children: Pathophysiology and management", section on 'Management of fever'</a>.)</p><p>No particular diet has had a major impact on outcomes of patients with acute hepatitis A. As a result, no specific diet is recommended, unless the patient has severely compromised hepatic function (ie, acute liver failure).</p><p>Patients rarely require hospitalization, except for brief admissions for hydration and evaluation, or for those who develop acute liver failure. The Pediatric Acute Liver Failure Study Group (PALF SG) criteria are used to identify such patients [<a href="#rid32">32,42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of known chronic liver disease</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of hepatic injury</p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time (PT) &gt;15 and/or international normalized ratio (INR) &gt;1.5 with encephalopathy</p><p class="bulletIndent1"><span class="glyph">●</span>PT &gt;20 and/or INR &gt;2.0 with or without encephalopathy</p><p></p><p>These criteria should be fulfilled within eight weeks from the onset of illness, and the above-described coagulopathy (prolonged PT and/or INR) should be unresponsive to <a class="drug drug_pediatric" data-topicid="12704" href="/d/drug information/12704.html" rel="external">vitamin K</a> therapy.</p><p>These patients require aggressive supportive therapy and should be transferred to a center capable of performing liver transplantation. (See  <a class="medical medical_review" href="/d/html/83172.html" rel="external">"Acute liver failure in children: Management, complications, and outcomes"</a>.)</p><p class="headingAnchor" id="H4283895077"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116507.html" rel="external">"Society guideline links: Pediatric liver disease"</a>.)</p><p class="headingAnchor" id="H25267267"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis A virus (HAV) infection occurs worldwide  (<a class="graphic graphic_figure graphicRef69392" href="/d/graphic/69392.html" rel="external">figure 3</a>). HAV is spread via the fecal-oral route. The majority of patients who acquire the illness have had personal contact with an infected person. The incidence among children has decreased substantially since the introduction of the HAV vaccine  (<a class="graphic graphic_figure graphicRef134981" href="/d/graphic/134981.html" rel="external">figure 1</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The incubation period for HAV is 15 to 50 days. HAV RNA can be detected in stools at least one week before the onset of histologic and biochemical evidence of hepatitis, and it can be detected for at least 33 days after the onset of disease. In neonates and younger children, HAV RNA can be detected in stools for several months. In the childcare setting, the spread of HAV usually takes place before the index case has been recognized. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HAV infection in children is typically an acute, self-limited illness associated with nonspecific symptoms, such as fever, malaise, anorexia, vomiting, nausea, abdominal pain or discomfort, and diarrhea. During the prodromal period, aminotransferases are typically elevated. Jaundice (conjugated hyperbilirubinemia) usually occurs one week after onset of symptoms, along with choluria (bilirubin in the urine) and mild hepatomegaly. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HAV disease tends to be more severe when acquired at older ages. Among younger children (under six years of age) with HAV infection, only one-third develop symptomatic hepatitis and this often lasts less than two weeks. In contrast, most older children and adults with HAV infection are jaundiced and have hepatomegaly, and they are usually symptomatic for several weeks. Acute liver failure is rare, occurring in less than 1 percent of cases. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of acute HAV infection is made by the detection of anti-HAV immunoglobulin M (IgM) in a patient with the typical clinical presentation. This antibody is positive at the onset of symptoms, peaks during the acute or early convalescent phase of the disease, and remains positive for approximately four to six months  (<a class="graphic graphic_figure graphicRef57931" href="/d/graphic/57931.html" rel="external">figure 4</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12935" href="/d/drug information/12935.html" rel="external">Hepatitis A vaccine</a> is part of the recommended childhood and adolescent immunization schedule in the United States. It is recommended as a two-dose series for all children beginning at one year of age and also for specific high-risk groups, including international travelers and patients with chronic liver disease. (See <a class="local">'Routine childhood vaccination'</a> above and  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Vaccination'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Post-exposure prophylaxis for individuals with recent exposure to HAV may be accomplished with the HAV vaccine or <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a>. Indications for and detailed recommendations about post-exposure prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Protection following exposure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – HAV infection in children is usually a minor and self-limited infection requiring no specific therapy. The usual supportive measures for fever and diarrhea may be undertaken. Patients rarely require hospitalization, except for those who develop acute liver failure. Children with HAV-related hepatic failure are candidates for liver transplantation. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Centers for Disease Control and Prevention. Viral Hepatitis Surveillance – United States. Available at: https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm (Accessed on February 13, 2022).</li><li><a class="nounderline abstract_t">Lemon SM, Jansen RW, Brown EA. Genetic, antigenic and biological differences between strains of hepatitis A virus. Vaccine 1992; 10 Suppl 1:S40.</a></li><li><a class="nounderline abstract_t">Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.</a></li><li><a class="nounderline abstract_t">Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005; 294:194.</a></li><li class="breakAll">Division of Viral Hepatitis. Hepatitis Surveillance Report - United States, 2011. United States Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA 2011.</li><li><a class="nounderline abstract_t">Daniels D, Grytdal S, Wasley A, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009; 58:1.</a></li><li><a class="nounderline abstract_t">Doshani M, Weng M, Moore KL, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness. MMWR Morb Mortal Wkly Rep 2019; 68:153.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Hepatitis A Questions and Answers for Health Professionals. Available at: https://www.cdc.gov/hepatitis/hav/havfaq.htm (Accessed on February 13, 2022).</li><li><a class="nounderline abstract_t">Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294:202.</a></li><li><a class="nounderline abstract_t">Belmaker I, Dukhan L, Yosef Y, et al. Elimination of hepatitis a infection outbreaks in day care and school settings in southern Israel after introduction of the national universal toddler hepatitis a immunization program. Pediatr Infect Dis J 2007; 26:36.</a></li><li><a class="nounderline abstract_t">Barkai G, Belmaker I, Givon-Lavi N, Dagan R. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community. Pediatr Infect Dis J 2009; 28:391.</a></li><li><a class="nounderline abstract_t">Van Damme P, Van Herck K. Effect of hepatitis A vaccination programs. JAMA 2005; 294:246.</a></li><li><a class="nounderline abstract_t">Hadler SC, Webster HM, Erben JJ, et al. Hepatitis A in day-care centers. A community-wide assessment. N Engl J Med 1980; 302:1222.</a></li><li><a class="nounderline abstract_t">Vernon AA, Schable C, Francis D. A large outbreak of hepatitis A in a day-care center: association with non-toilet-trained children and persistence of IgM antibody to hepatitis A virus. Am J Epidemiol 1982; 115:325.</a></li><li><a class="nounderline abstract_t">Fischer GE, Teshale EH, Miller C, et al. Hepatitis A among international adoptees and their contacts. Clin Infect Dis 2008; 47:812.</a></li><li><a class="nounderline abstract_t">Noble RC, Kane MA, Reeves SA, Roeckel I. Posttransfusion hepatitis A in a neonatal intensive care unit. JAMA 1984; 252:2711.</a></li><li><a class="nounderline abstract_t">Klein BS, Michaels JA, Rytel MW, et al. Nosocomial hepatitis A. A multinursery outbreak in Wisconsin. JAMA 1984; 252:2716.</a></li><li><a class="nounderline abstract_t">Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 1991; 164:476.</a></li><li><a class="nounderline abstract_t">Pinto MA, Marchevsky RS, Baptista ML, et al. Experimental hepatitis A virus (HAV) infection in Callithrix jacchus: early detection of HAV antigen and viral fate. Exp Toxicol Pathol 2002; 53:413.</a></li><li><a class="nounderline abstract_t">Bruisten SM, van Steenbergen JE, Pijl AS, et al. Molecular epidemiology of hepatitis A virus in Amsterdam, the Netherlands. J Med Virol 2001; 63:88.</a></li><li><a class="nounderline abstract_t">Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med 1985; 313:1059.</a></li><li><a class="nounderline abstract_t">Vallbracht A, Fleischer B, Busch FW. Hepatitis A: hepatotropism and influence on myelopoiesis. Intervirology 1993; 35:133.</a></li><li><a class="nounderline abstract_t">Fleischer B, Fleischer S, Maier K, et al. Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology 1990; 69:14.</a></li><li><a class="nounderline abstract_t">Baba M, Hasegawa H, Nakayabu M, et al. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. J Clin Lab Immunol 1993; 40:47.</a></li><li><a class="nounderline abstract_t">Rezende G, Roque-Afonso AM, Samuel D, et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 2003; 38:613.</a></li><li class="breakAll">American Academy of Pediatrics. Hepatitis A. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.373.</li><li><a class="nounderline abstract_t">Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985; 122:226.</a></li><li><a class="nounderline abstract_t">Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 1995; 171 Suppl 1:S15.</a></li><li><a class="nounderline abstract_t">Gordon SC, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984; 101:635.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Hepatitis Surveillance Report. United States Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA 2011.</li><li><a class="nounderline abstract_t">Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286.</a></li><li><a class="nounderline abstract_t">Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148:652.</a></li><li class="breakAll">Terrault NA, Wright TL. Viral hepatitis A through G. In: Gastrointestinal and Liver Disease, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, Philadelphia 1998. p.1129.</li><li><a class="nounderline abstract_t">Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 1992; 10 Suppl 1:S18.</a></li><li><a class="nounderline abstract_t">Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991; 337:1183.</a></li><li><a class="nounderline abstract_t">Skoog SM, Rivard RE, Batts KP, Smith CI. Autoimmune hepatitis preceded by acute hepatitis A infection. Am J Gastroenterol 2002; 97:1568.</a></li><li><a class="nounderline abstract_t">Vento S, Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis? Autoimmun Rev 2004; 3:61.</a></li><li><a class="nounderline abstract_t">Kao HW, Ashcavai M, Redeker AG. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. Hepatology 1984; 4:933.</a></li><li><a class="nounderline abstract_t">Ashur Y, Adler R, Rowe M, Shouval D. Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. Vaccine 1999; 17:2290.</a></li><li><a class="nounderline abstract_t">Jilg W, Bittner R, Bock HL, et al. Vaccination against hepatitis A: comparison of different short-term immunization schedules. Vaccine 1992; 10 Suppl 1:S126.</a></li><li><a class="nounderline abstract_t">Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Narkewicz MR, Dell Olio D, Karpen SJ, et al. Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J Pediatr 2009; 155:801.</a></li></ol></div><div id="topicVersionRevision">Topic 5942 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Centers for Disease Control and Prevention. Viral Hepatitis Surveillance – United States. Available at: https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm (Accessed on February 13, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335657" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Genetic, antigenic and biological differences between strains of hepatitis A virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16708058" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014593" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of hepatitis A in the United States in the era of vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014593" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of hepatitis A in the United States in the era of vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19478727" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Surveillance for acute viral hepatitis - United States, 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763295" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763295" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014594" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence of hepatitis A in Israel following universal immunization of toddlers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17195703" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Elimination of hepatitis a infection outbreaks in day care and school settings in southern Israel after introduction of the national universal toddler hepatitis a immunization program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19295466" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014600" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of hepatitis A vaccination programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6245363" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hepatitis A in day-care centers. A community-wide assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6278926" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A large outbreak of hepatitis A in a day-care center: association with non-toilet-trained children and persistence of IgM antibody to hepatitis A virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18684098" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hepatitis A among international adoptees and their contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6492349" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Posttransfusion hepatitis A in a neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6492350" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nosocomial hepatitis A. A multinursery outbreak in Wisconsin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1651359" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11930901" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Experimental hepatitis A virus (HAV) infection in Callithrix jacchus: early detection of HAV antigen and viral fate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11170043" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Molecular epidemiology of hepatitis A virus in Amsterdam, the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2413356" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Type A viral hepatitis. New developments in an old disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8407240" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hepatitis A: hepatotropism and influence on myelopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2312151" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7932628" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12939587" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Viral and clinical factors associated with the fulminant course of hepatitis A infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12939587" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Viral and clinical factors associated with the fulminant course of hepatitis A infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3860002" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Frequency of illness associated with epidemic hepatitis A virus infections in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7876641" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical manifestations of hepatitis A: recent experience in a community teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486595" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prolonged intrahepatic cholestasis secondary to acute hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486595" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prolonged intrahepatic cholestasis secondary to acute hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445408" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16737880" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16737880" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1475999" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Atypical clinical manifestations of hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1673738" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12094893" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Autoimmune hepatitis preceded by acute hepatitis A infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871651" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Is there a role for viruses in triggering autoimmune hepatitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6090293" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The persistence of hepatitis A IgM antibody after acute clinical hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10403597" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335642" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Vaccination against hepatitis A: comparison of different short-term immunization schedules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32614811" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643443" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
